Shaperon Inc. Logo

Shaperon Inc.

Develops inflammasome inhibitors & nanobodies for inflammatory diseases and cancer.

378800 | KO

Overview

Corporate Details

ISIN(s):
KR7378800007
LEI:
Country:
South Korea
Address:
서울특별시 강남구 자곡로 174-10 강남에이스타워 606호(자곡동), 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Shaperon Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory diseases and cancer. The company specializes in creating innovative inflammasome inhibitors, utilizing a unique mechanism of action involving GPCR19-P2X7 modulation to suppress immune responses. Its development pipeline targets conditions such as atopic dermatitis and other immune-mediated inflammatory disorders. In addition to small molecules, Shaperon develops nanobody therapeutics for cancer immunotherapy, leveraging proprietary immunized libraries and high-throughput screening technologies. Founded in 2008, the company completed a successful initial public offering in October 2022.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-16 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 86.0 KB
2025-09-16 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.0 KB
2025-09-16 00:00
Share Issue/Capital Change
유상증자1차발행가액결정 (주주배정후 실권주 일반공모)
Korean 7.6 KB
2025-09-16 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 40.4 KB
2025-09-16 00:00
Registration Form
[발행조건확정]증권신고서(지분증권)
Korean 435.2 KB
2025-09-16 00:00
Prospectus
투자설명서
Korean 2.7 MB
2025-09-16 00:00
Share Issue/Capital Change
권리락 (유상증자)
Korean 3.5 KB
2025-09-12 00:00
Director's Dealing
임원ㆍ주요주주특정증권등거래계획보고서
Korean 42.6 KB
2025-09-01 00:00
Registration Form
[기재정정]증권신고서(지분증권) (2025.10)
Korean 3.2 MB
2025-08-18 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 32.0 KB
2025-08-18 00:00
Registration Form
증권신고서(지분증권) (2025.10)
Korean 2.5 MB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.1 MB
2025-03-26 00:00
Post-Annual General Meeting Information
[기재정정]정기주주총회결과
Korean 31.2 KB
2025-03-26 00:00
Board/Management Information
[기재정정]사외이사의선임ㆍ해임또는중도퇴임에관한신고
Korean 13.4 KB

Automate Your Workflow. Get a real-time feed of all Shaperon Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Shaperon Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Shaperon Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ANAVEX LIFE SCIENCES CORP. Logo
Developing precision therapeutics for neurodegenerative and CNS disorders.
United States of America
AVXL
Anbio Biotechnology Logo
Develops and supplies in vitro diagnostic solutions for human and veterinary markets.
United States of America
NNNN
Anebulo Pharmaceuticals, Inc. Logo
Clinical-stage biotech developing an antidote for acute cannabinoid intoxication in ER patients.
United States of America
ANEB
AnGes, Inc. Logo
Develops gene-based medicines like HGF gene therapy, DNA vaccines, and NF-kB decoys.
Japan
4563
ANIMALCARE GROUP PLC Logo
Develops & sells veterinary prescription & OTC medicines for professionals worldwide.
United Kingdom
ANCR
ANI PHARMACEUTICALS INC Logo
Develops, manufactures, and markets branded/generic drugs and OTCs for niche therapeutic areas.
United States of America
ANIP
Annexin Pharmaceuticals AB Logo
Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.
Sweden
ANNX
Annexon, Inc. Logo
Developing C1q inhibitors for autoimmune, neurodegenerative, and ophthalmic diseases.
United States of America
ANNX
ANTEROGEN CO., LTD. Logo
Develops and commercializes adult stem cell therapies and orphan drugs for medical conditions.
South Korea
065660
Antibiotice S.A. Logo
Develops and manufactures generic medicines and APIs, specializing in anti-infectives.
Romania
ATB

Talk to a Data Expert

Have a question? We'll get back to you promptly.